NCT00401024 is a Phase 1 clinical trial of imatinib mesylate in Brain and Central Nervous System Tumors, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

Who is sponsoring NCT00401024?

NCT00401024 is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

What drugs are being tested in NCT00401024?

Interventions in NCT00401024: imatinib mesylate, pharmacological study, conventional surgery.

What condition does NCT00401024 study?

NCT00401024 studies Brain and Central Nervous System Tumors.

Is NCT00401024 still recruiting?

NCT00401024 is currently completed. Last updated 28 June 2018.

Last reviewed 2018-06-28 · How we verify

NCT00401024

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Tumor Tissue Analysis in Patients Receiving Imatinib Mesylate for Malignant Glioma

Completed Phase 1 Last updated 28 June 2018

What this trial tests

Phase 1 trial testing imatinib mesylate in Brain and Central Nervous System Tumors in 3 participants. Completed in 11 November 2008.

Timeline

12 October 2006

Primary endpoint
4 February 2008

11 November 2008

Quick facts

Lead sponsor	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	3
Start date	12 October 2006
Primary completion	4 February 2008
Estimated completion	11 November 2008
Sites	1 location across United States

Drugs / interventions tested

imatinib mesylate — full drug profile →
pharmacological study — full drug profile →
conventional surgery

Conditions studied

Brain and Central Nervous System Tumors — all drugs for Brain and Central Nervous System Tumors →

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins — full company profile →

Who can join

Adults 18 to 120, any sex, with Brain and Central Nervous System Tumors. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

RATIONALE: Collecting samples of tumor tissue and blood from patients with cancer to study in the laboratory may help doctors learn how patients respond to treatment. PURPOSE: This clinical trial is looking at tumor tissue samples from patients receiving imatinib mesylate for malignant glioma to see how much imatinib mesylate is found in the tumor tissue.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

The Molecular and Microenvironmental Landscape of Glioblastomas: Implications for the Novel Treatment Choices.
Di Cintio F, Dal Bo M, Baboci L, De Mattia E, et al · · 2020 · cited 28× · PMID 33324155 · DOI 10.3389/fnins.2020.603647

Verify or expand the search:

Other trials of imatinib mesylate

Trials testing the same drug.

NCT01742299 — Study to Allow Access to Imatinib for Patients Who Are on Imatinib Treatment in a Novartis-sponsored Study and Are Benef · Phase 4 · active not recruiting
NCT00867113 — Five Year Adjuvant Imatinib Mesylate (Gleevec®) in Gastrointestinal Stromal Tumor (GIST) · Phase 2 · completed
NCT00483366 — Imatinib Mesylate, Gemcitabine, and Capecitabine in Treating Patients With Advanced Solid Tumors · Phase 1 · completed
NCT00323063 — Gemcitabine +/- Imatinib Mesylate, Patients w/Previously Treated Metastatic Breast Cancer · Phase 2 · terminated
NCT00010049 — Imatinib Mesylate in Treating Patients With Recurrent Malignant Glioma or Meningioma · Phase 1, PHASE2 · completed

Other recruiting trials for Brain and Central Nervous System Tumors

Currently open trials in the same condition.

NCT00978458 — Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma · Phase 3 · active not recruiting

Other Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins trials

Trials by the same sponsor.

NCT07424222 — Ruxolitinib for Immune Effector Cell Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (RISE) · Phase 1 · not yet recruiting
NCT06210854 — Assessing Administration of pBI-11 Via Electroporation for the Treatment of Patients With HPV16/18+ · Phase 2 · not yet recruiting
NCT07360119 — Total Pancreatectomy With Islet Autotransplantation (TPIAT) for High-Risk Patients With Pancreatic Tumors · NA · not yet recruiting
NCT07140315 — DK222 Study at Hopkins · Phase 1 · recruiting
NCT07071155 — Momelotinib in Combination With Hypomethylating Agent for Chronic Phase Myelodysplastic Syndromes/Myeloproliferative Ove · EARLY_PHASE1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00401024 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Last refreshed: 28 June 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00401024.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing